InflaRx N.V. Logo

InflaRx N.V.

IF0.DE

(1.0)
Stock Price

2,94 EUR

-38.53% ROA

-37.49% ROE

-4.05x PER

Market Cap.

129.914.968,00 EUR

1.17% DER

0% Yield

-41604.56% NPM

InflaRx N.V. Stock Analysis

InflaRx N.V. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

InflaRx N.V. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (1%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 PBV

The stock's PBV ratio (1.1x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

4 ROE

Negative ROE (-35.78%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-28.31%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

InflaRx N.V. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

InflaRx N.V. Technical Stock Analysis
# Analysis Recommendation

InflaRx N.V. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

InflaRx N.V. Revenue
Year Revenue Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 243.212 100%
2023 63.089 -285.51%
2024 144.148 56.23%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

InflaRx N.V. Research and Development Expenses
Year Research and Development Expenses Growth
2015 3.478.000
2016 5.278.000 34.1%
2017 14.415.000 63.39%
2018 25.028.000 42.4%
2019 44.582.136 43.86%
2020 25.684.140 -73.58%
2021 35.697.935 28.05%
2022 37.526.090 4.87%
2023 29.222.164 -28.42%
2023 41.024.131 28.77%
2024 29.207.240 -40.46%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

InflaRx N.V. General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 438.000
2016 1.844.000 76.25%
2017 5.138.000 64.11%
2018 12.787.000 59.82%
2019 12.501.048 -2.29%
2020 8.467.203 -47.64%
2021 11.984.722 29.35%
2022 14.869.564 19.4%
2023 11.590.928 -28.29%
2023 14.216.409 18.47%
2024 14.316.600 0.7%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

InflaRx N.V. EBITDA
Year EBITDA Growth
2015 -3.821.000
2016 -7.070.000 45.95%
2017 -21.938.000 67.77%
2018 -29.641.000 25.99%
2019 -56.799.952 47.82%
2020 -32.468.389 -74.94%
2021 -46.899.992 30.77%
2022 -31.285.061 -49.91%
2023 -38.402.124 18.53%
2023 -40.222.248 4.53%
2024 -45.412.120 11.43%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

InflaRx N.V. Gross Profit
Year Gross Profit Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 -777.252 100%
2023 -469.173 -65.66%
2024 -737.936 36.42%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

InflaRx N.V. Net Profit
Year Net Profit Growth
2015 -4.917.000
2016 -8.939.000 44.99%
2017 -24.238.000 63.12%
2018 -29.815.000 18.71%
2019 -49.741.461 40.06%
2020 -34.009.614 -46.26%
2021 -45.654.828 25.51%
2022 -27.042.313 -68.83%
2023 -29.805.640 9.27%
2023 -42.667.529 30.14%
2024 -38.628.944 -10.45%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

InflaRx N.V. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 0
2016 0 0%
2017 -3 100%
2018 -1 -100%
2019 -2 0%
2020 -1 0%
2021 -1 0%
2022 -1 0%
2023 0 0%
2023 -1 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

InflaRx N.V. Free Cashflow
Year Free Cashflow Growth
2015 -3.321.000
2016 -5.046.000 34.19%
2017 -12.301.000 58.98%
2018 -24.518.000 49.83%
2019 -43.799.380 44.02%
2020 -36.621.850 -19.6%
2021 -39.974.528 8.39%
2022 -33.905.208 -17.9%
2023 -5.273.238 -542.97%
2023 -37.894.066 86.08%
2024 -14.884.433 -154.59%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

InflaRx N.V. Operating Cashflow
Year Operating Cashflow Growth
2015 -3.308.000
2016 -4.993.000 33.75%
2017 -12.152.000 58.91%
2018 -23.712.000 48.75%
2019 -43.204.491 45.12%
2020 -36.527.661 -18.28%
2021 -39.936.750 8.54%
2022 -33.742.817 -18.36%
2023 -5.251.969 -542.48%
2023 -37.812.966 86.11%
2024 -14.868.364 -154.32%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

InflaRx N.V. Capital Expenditure
Year Capital Expenditure Growth
2015 13.000
2016 53.000 75.47%
2017 149.000 64.43%
2018 806.000 81.51%
2019 594.889 -35.49%
2020 94.189 -531.59%
2021 37.778 -149.32%
2022 162.391 76.74%
2023 21.269 -663.51%
2023 81.100 73.77%
2024 16.069 -404.7%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

InflaRx N.V. Equity
Year Equity Growth
2015 -17.619.000
2016 -25.689.000 31.41%
2017 119.429.000 121.51%
2018 151.391.000 21.11%
2019 107.146.672 -41.29%
2020 77.863.879 -37.61%
2021 105.280.996 26.04%
2022 88.349.440 -19.16%
2023 102.581.731 13.87%
2023 117.990.263 13.06%
2024 94.759.659 -24.52%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

InflaRx N.V. Assets
Year Assets Growth
2015 3.586.000
2016 29.518.000 87.85%
2017 124.213.000 76.24%
2018 159.214.000 21.98%
2019 121.576.557 -30.96%
2020 88.215.834 -37.82%
2021 125.139.120 29.51%
2022 102.399.660 -22.21%
2023 120.208.552 14.81%
2023 129.485.304 7.16%
2024 107.095.235 -20.91%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

InflaRx N.V. Liabilities
Year Liabilities Growth
2015 21.205.000
2016 55.207.000 61.59%
2017 4.784.000 -1053.99%
2018 7.823.000 38.85%
2019 14.429.885 45.79%
2020 10.351.954 -39.39%
2021 19.858.124 47.87%
2022 14.050.220 -41.34%
2023 17.626.822 20.29%
2023 11.495.042 -53.34%
2024 12.335.577 6.81%

InflaRx N.V. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.73
Price to Earning Ratio
-4.05x
Price To Sales Ratio
1310.6x
POCF Ratio
-3.96
PFCF Ratio
-3.07
Price to Book Ratio
1.76
EV to Sales
1068.51
EV Over EBITDA
-2.53
EV to Operating CashFlow
-2.51
EV to FreeCashFlow
-2.51
Earnings Yield
-0.25
FreeCashFlow Yield
-0.33
Market Cap
0,13 Bil.
Enterprise Value
0,11 Bil.
Graham Number
5.22
Graham NetNet
1.39

Income Statement Metrics

Net Income per Share
-0.73
Income Quality
1.02
ROE
-0.37
Return On Assets
-0.39
Return On Capital Employed
-0.49
Net Income per EBT
1
EBT Per Ebit
0.88
Ebit per Revenue
-472.15
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
143.12
Research & Developement to Revenue
338.9
Stock Based Compensation to Revenue
41.04
Gross Profit Margin
-6.59
Operating Profit Margin
-472.15
Pretax Profit Margin
-416.05
Net Profit Margin
-416.05

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.74
Free CashFlow per Share
-0.74
Capex to Operating CashFlow
0
Capex to Revenue
-0.92
Capex to Depreciation
-0.17
Return on Invested Capital
-0.49
Return on Tangible Assets
-0.39
Days Sales Outstanding
7856
Days Payables Outstanding
3688.75
Days of Inventory on Hand
5357.13
Receivables Turnover
0.05
Payables Turnover
0.1
Inventory Turnover
0.07
Capex per Share
-0

Balance Sheet

Cash per Share
1,48
Book Value per Share
1,67
Tangible Book Value per Share
1.67
Shareholders Equity per Share
1.67
Interest Debt per Share
0.02
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
0.57
Current Ratio
8.9
Tangible Asset Value
0,09 Bil.
Net Current Asset Value
0,09 Bil.
Invested Capital
0.01
Working Capital
0,09 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
11208226
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

InflaRx N.V. Dividends
Year Dividends Growth

InflaRx N.V. Profile

About InflaRx N.V.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

CEO
Dr. Niels C. Riedemann M.D., P
Employee
62
Address
Winzerlaer Str. 2
Jena, 07745

InflaRx N.V. Executives & BODs

InflaRx N.V. Executives & BODs
# Name Age
1 Mr. Jan Medina CFA
Head of Investor Relations & Vice President
70
2 Ms. Derval O'Carroll
Senior Vice President and Global Head of Regulatory Affairs & Compliance
70
3 Ms. Nicole Bertsch
Senior Director & Head of Human Resources
70
4 Dr. Camilla Chong M.D.
Chief Medical Officer
70
5 Dr. Bruce P. Burnett Ph.D.
Vice President & Head of Medical Affairs
70
6 Mr. Christian Schmid
Vice President and Head of Legal Affairs & General Counsel
70
7 Dr. Maria Habel PH.D.
Vice President, Head of Preclinical R&D and QC
70
8 Dr. Niels C. Riedemann M.D., Ph.D.
Co-Founder, Chief Executive Officer & Executive Director
70
9 Prof. Renfeng Guo M.D.
Co-Founder, Chief Scientific Officer & Executive Director
70
10 Dr. Thomas Taapken Ph.D.
Chief Financial Officer
70

InflaRx N.V. Competitors